Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance and Long-term Extension Study of Risankizumab in Crohn's Disease
2023-506399-28-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 48
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Risankizumab maintenance with Placebo maintenance (2 arms). Primary endpoints: Clinical remission at Week 52 (primary), Endoscopic response at Week 52 (primary) and 1 more. Planned start Jun 2024; status: authorised.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2023-506399-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506399-28-00.